Gut microbiota and liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 6, 2014, Pages 1139-1148

  Goel, Amit ^a   Gupta, Mahesh ^a   Aggarwal, Rakesh ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Alcoholic liver disease; Encephalopathy; Gastroenterology; Hepatology; Microbial pathogenesis; NAFLD; NASH; Pathogenesis; Portal hypertension

Indexed keywords

LACTITOL; LACTULOSE; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; RNA 16S;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; DNA MICROARRAY; FATTY LIVER; FIBROGENESIS; GERMFREE ANIMAL; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; LIVER CIRRHOSIS; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; RNA SEQUENCE; ANIMAL; BACTERIA; DISEASE COURSE; DISEASE MODEL; DNA FINGERPRINTING; GASTROINTESTINAL TRACT; GENETICS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOGENICITY; PROCEDURES;

ANIMALS; BACTERIA; BACTERIOLOGICAL TECHNIQUES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA FINGERPRINTING; FATTY LIVER; GASTROINTESTINAL TRACT; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84900553456     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12556     Document Type: Article

References (76)

1. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol. Rev. 2010; 90: 859-904.
2. Qin J, Li R, Raes J etal. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
3. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 13780-13785.
4. Faith JJ, Guruge JL, Charbonneau M etal. The long-term stability of the human gut microbiota. Science 2013; 341: 1237439.
5. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 2008; 27: 104-119.
6. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012; 336: 1268-1273.
7. Eckburg PB, Bik EM, Bernstein CN etal. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638.
8. Engel P, Martinson VG, Moran NA. Functional diversity within the simple gut microbiota of the honey bee. Proc. Natl Acad. Sci. U.S.A. 2012; 109: 11002-11007.
9. Clarridge JE 3rd. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin. Microbiol. Rev. 2004; 17: 840-862.
10. Margulies M, Egholm M, Altman WE. Genome sequencing in microfabricated highdensity picolitre reactors. Nature 2005; 437: 376-380.
11. Turnbaugh PJ, Hamady M, Yatsunenko T etal. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484.
12. Mahowald MA, Rey FE, Seedorf H etal. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc. Natl Acad. Sci. U.S.A. 2009; 106: 5859-5864.
13. Samuel BS, Gordon JI. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc. Natl Acad. Sci. U.S.A. 2006; 103: 10011-10016.
14. Schaedler RW, Dubs R, Costello R. Association of germfree mice with bacteria isolated from normal mice. J. Exp. Med. 1965; 22: 77-82.
15. Stehr M, Greweling MC, Tischer S etal. Charles River altered Schaedler flora (CRASF) remained stable for four years in a mouse colony housed in individually ventilated cages. Lab Anim. 2009; 43: 362-370.
16. Gill SR, Pop M, Deboy RT etal. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359.
17. Hirayama K, Itoh K. Human flora-associated (HFA) animals as a model for studying the role of intestinal flora in human health and disease. Curr. Issues Intest. Microbiol. 2005; 6: 69-75.
18. Catala M, Anton A, Portoles MT. Characterization of the simultaneous binding of Escherichia coli endotoxin to Kupffer and endothelial liver cells by flow cytometry. Cytometry 1999; 36: 123-130.
19. Compare D, Coccoli P, Rocco A etal. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2012; 22: 471-476.
20. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 691-701.
21. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 979-984.
22. Backhed F, Ding H, Wang T etal. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. U.S.A. 2004; 101: 15718-15723.
23. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
24. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
25. Zhang H, DiBaise JK, Zuccolo A etal. Human gut microbiota in obesity and after gastric bypass. Proc. Natl Acad. Sci. U.S.A. 2009; 106: 2365-2370.
26. Sabate JM, Jouet P, Harnois F etal. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes. Surg. 2008; 18: 371-377.
27. Caricilli AM, Saad MJ. The role of gut microbiota on insulin resistance. Nutrients 2013; 5: 829-851.
28. Volynets V, Kuper MA, Strahl S etal. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig. Dis. Sci. 2012; 57: 1932-1941.
29. Creely SJ, McTernan PG, Kusminski CM etal. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2007; 292: E740-747.
30. Li Z, Yang S, Lin H etal. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350.
31. Day CP, James OF. Steatohepatitis: a tale of two "hits." Gastroenterology 1998; 114: 842-845.
32. Gao B, Jeong WI, Tian Z. Liver: an organ with predominant innate immunity. Hepatology 2008; 47: 729-736.
33. Elinav E, Strowig T, Kau AL etal. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745-757.
34. Henao-Mejia J, Elinav E, Jin C etal. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185.
35. Ye D, Li FY, Lam KS etal. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012; 61: 1058-1067.
36. Csak T, Velayudham A, Hritz I etal. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2011; 300: G433-441.
37. Crespo J, Cayon A, Fernandez-Gil P etal. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163.
38. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000; 119: 1340-1347.
39. Sarkola T, Eriksson CJ. Effect of 4-methylpyrazole on endogenous plasma ethanol and methanol levels in humans. Alcohol. Clin. Exp. Res. 2001; 25: 513-516.
40. Zhu L, Baker SS, Gill C etal. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609.
41. Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS ONE 2010; 5: e9570.
42. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50: 638-644.
43. Mutlu EA, Gillevet PM, Rangwala H etal. Colonic microbiome is altered in alcoholism. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G966-978.
44. Mukhopadhya I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? Nat. Rev. Gastroenterol. Hepatol. 2012; 9: 219-230.
45. Hartmann P, Chen WC, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front. Physiol. 2012; 3: 402.
46. Amin PB, Diebel LN, Liberati DM. Dose-dependent effects of ethanol and E. coli on gut permeability and cytokine production. J. Surg. Res. 2009; 157: 187-192.
47. Basuroy S, Sheth P, Mansbach CM, Rao RK. Acetaldehyde disrupts tight junctions and adherens junctions in human colonic mucosa: protection by EGF and L-glutamine. Am. J. Physiol. Gastrointest. Liver Physiol. 2005; 289: G367-375.
48. Forsyth CB, Tang Y, Shaikh M, Zhang L, Keshavarzian A. Role of snail activation in alcohol-induced iNOS-mediated disruption of intestinal epithelial cell permeability. Alcohol. Clin. Exp. Res. 2011; 35: 1635-1643.
49. Tang Y, Forsyth CB, Farhadi A etal. Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. Alcohol. Clin. Exp. Res. 2009; 33: 1220-1230.
50. Lakshmi CP, Ghoshal UC, Kumar S etal. Frequency and factors associated with small intestinal bacterial overgrowth in patients with cirrhosis of the liver and extra hepatic portal venous obstruction. Dig. Dis. Sci. 2010; 55: 1142-1148.
51. Gupta A, Dhiman RK, Kumari S etal. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J. Hepatol. 2010; 53: 849-855.
52. Chen Y, Yang F, Lu H etal. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54: 562-572.
53. Gomez-Hurtado I, Santacruz A, Peiro G etal. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS ONE 2011; 6: e23037.
54. Such J, Frances R, Munoz C etal. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36: 135-141.
55. Papp M, Norman GL, Vitalis Z etal. Presence of anti-microbial antibodies in liver cirrhosis-a tell-tale sign of compromised immunity? PLoS ONE 2010; 5: e12957.
56. Scarpellini E, Valenza V, Gabrielli M etal. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am. J. Gastroenterol. 2010; 105: 323-327.
57. Steffen EK, Berg RD, Deitch EA. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J. Infect. Dis. 1988; 157: 1032-1038.
58. Garcia-Tsao G. Spontaneous bacterial peritonitis. Gastroenterol. Clin. North Am. 1992; 21: 257-275.
59. Natarajan SK, Ramamoorthy P, Thomas S etal. Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: changes in glycosylation and luminal bacteria. Hepatology 2006; 43: 837-846.
60. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-1449.
61. Llovet JM, Bartoli R, March F etal. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J. Hepatol. 1998; 28: 307-313.
62. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J. Hepatol. 1997; 26: 1372-1378.
63. Garcia-Gonzalez M, Boixeda D, Herrero D, Burgaleta C. Effect of granulocyte-macrophage colony-stimulating factor on leukocyte function in cirrhosis. Gastroenterology 1993; 105: 527-531.
64. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986; 6: 252-262.
65. Such J, Guarner C, Enriquez J, Rodriguez JL, Seres I, Vilardell F. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J. Hepatol. 1988; 6: 80-84.
66. Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984; 4: 53-58.
67. Lamontagne A, Long RE, Comunale MA etal. Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection. PLoS ONE 2013; 8: e64992.
68. Inamura T, Miura S, Tsuzuki Y etal. Alteration of intestinal intraepithelial lymphocytes and increased bacterial translocation in a murine model of cirrhosis. Immunol. Lett. 2003; 90: 3-11.
69. Dhiman RK. Gut microbiota and hepatic encephalopathy. Metab. Brain Dis. 2013; 28: 321-326.
70. Wright G, Davies NA, Shawcross DL etal. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 2007; 45: 1517-1526.
71. Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment. Pharmacol. Ther. 2011; 33: 662-671.
72. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008; 27: 218-224.
73. Yu LX, Yan HX, Liu Q etal. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010; 52: 1322-1333.
74. Dapito DH, Mencin A, Gwak GY etal. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516.
75. Maeda S. NF-kappaB, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol. Res. Pract. 2010; 2010: 367694.
76. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005; 5: 749-759.